Search Results

You are looking at 61 - 70 of 542 items for :

  • "pathology" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Giuseppe Curigliano

.m. Patient: “Doctor, I’m terrified. The pathology report says ‘invasive carcinoma.’ ‘Invasive’ means cancer, doesn’t it? I’ll need chemotherapy. I’ll lose my hair. I won’t see my children grow up.” Across borders and social-cultural groups of patients, a

Full access

Siddhartha Yadav, Sri Harsha Tella, Anuhya Kommalapati, Kristin Mara, Kritika Prasai, Mohamed Hamdy Mady, Mohamed Hassan, Rory L. Smoot, Sean P. Cleary, Mark J. Truty, Lewis R. Roberts, and Amit Mahipal

diagnosis. 5 The current AJCC TNM staging system for GBC is primarily based on surgical pathology. 6 It relies on accurate evaluation of tumor infiltration into the layers of gallbladder, which can only be achieved through complete surgical excision of the

Full access

Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor

*, and BRCA2 I605fs*11 ( Figure 2A ). Figure 1 Imaging and pathology reveal ambiguous diagnosis. (A) Coronal CT of the abdomen shows confluent retroperitoneal and porta hepatis lymphadenopathy (top arrows) resulting in moderate obstruction of the

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

ovarian pathology. This raises the issue of determining menopausal status at the start of, during, and after therapy. For example, patients may become amenorrheic during adjuvant chemotherapy without permanent loss of ovarian hormone production. Thus, the

Full access

Henry G. Kaplan, Steven Rostad, Jeffrey S. Ross, Siraj M. Ali, and Sherri Z. Millis

/RAF alterations, and other genomic alterations in all MPNSTs studied at Swedish Cancer Institute and Foundation Medicine during the past 12 years. Patients and Methods Patients from the Swedish Cancer Institute pathology archives were identified under an

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff

translation? A systematic database of gene expression in breast cancer . Pathobiology 2008 ; 75 : 112 – 118 . 110 Allred DC . The utility of conventional and molecular pathology in managing breast cancer . Breast Cancer Res 2008 ; 10 ( Suppl

Full access

Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos

were added to determine the maximum dose to that site. Notably, no patient received RT after the diagnosis of NMSC. Nonmelanoma Skin Cancer LTFU and patient dermatology and pathology records were used to determine the location of each NMSC. A lesion was

Full access

Derek J. Erstad, Mariela Blum, Jeannelyn S. Estrella, Prajnan Das, Bruce D. Minsky, Jaffer A. Ajani, Paul F. Mansfield, Naruhiko Ikoma, and Brian D. Badgwell

evidence of nodal disease on clinical staging despite positive final pathology. Among the primary tumors analyzed, 62% were category pT3–4, 67% had a poor or anaplastic grade, 19% had signet features, and <1% had linitis. Only 53% of patients had documented

Full access

Xiao Li, Xuan Rao, Ming-Jing Wei, Wei-Guo Lu, Xing Xie, and Xin-Yu Wang

accumulating evidence from high-quality clinical trials. The American Society for Colposcopy and Cervical Pathology (ASCCP) also recommends primary HPV testing or cotesting (HPV testing combined with cytology) for CC screening rather than cytology alone. 6

Full access

Hepatobiliary cancers are both common and highly lethal worldwide. However, in the United States, the incidence of hepatobiliary cancer is relatively low, with approximately 23,700 patients newly diagnosed each year. Gallbladder cancer is the most common of the hepatobiliary malignancies, accounting for approximately 30% of newly diagnosed cases in the United States. Along with summaries of the NCCN guidelines for the 4 subtypes of hepatobiliary cancer, this article includes a brief discussion of the epidemiology, pathology, etiology, staging, diagnosis, and treatment of each subtype.

For the most recent version of the guidelines, please visit